Altria Group, Inc. · MO · FY2026 Q1 · Calendar Q2 2026

Altria Q1 2026: EPS Beats 5.6% as Marlboro Hits 59.5% Premium Share and on! PLUS Goes Nationwide

Altria delivered a stronger-than-expected Q1 FY2026, with adjusted diluted EPS of $1.32 (up 7.3% YoY) beating consensus by 5.6% and revenue of $4.76B exceeding estimates by 3.9%. The beat was driven by Marlboro's premium share gains (59.5%) and expanding smoke-free penetration via on! PLUS, which reached nationwide availability at ~100,000 stores. Despite the strong start, management reaffirmed rather than raised full-year EPS guidance of $5.56-$5.72, signaling a more conservative H2 outlook and drawing analyst scrutiny. The stock surged 6.5% on the report before drifting -4.2% in subsequent sessions, suggesting the market initially rewarded the beat but reconsidered the unchanged guidance and ongoing macro headwinds. Compared to Q4 2025, where EPS grew 4.4% and the focus was on initial FDA authorizations and the duty drawback program launch, Q1 2026 showed accelerating EPS growth…

Reported Before market openNYSEConsumer Defensive $121.72B market cap
100quality score

Company context

Snapshot as of publication

Operating across the United States through its subsidiaries, Altria Group, Inc. is a prominent manufacturer and marketer of both combustible and oral tobacco items. Its portfolio features cigarettes, primarily under the iconic Marlboro brand, alongside cigars and pipe tobacco mainly offered as Black & Mild. The enterprise further provides an assortment of moist smokeless tobacco products, including Copenhagen, Skoal, Red Seal, and Husky, in addition to its on! brand of oral nicotine pouches. Altria distributes its merchandise chiefly to wholesale partners, such as independent distributors, and directly to substantial retail organizations, including major chain stores. The corporation, founded in 1822, maintains its principal offices in Richmond, Virginia.

Earnings scorecard

Reported versus consensus
Reported EPS $1.32 Consensus $1
EPS surprise +5.6% Reported versus consensus
Reported revenue $4.76B Consensus $4.58B
Revenue surprise +3.9% Reported versus consensus

Earnings History

Estimate Beat Miss Match
MO EPS earnings history estimate and actual scatter chart 8 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $1.17 Q4 '23 actual $1.18, match Q1 '24 estimate $1.15 Q1 '24 actual $1.15, match Q2 '24 estimate $1.34 Q2 '24 actual $1.31, miss Q3 '24 estimate $1.35 Q3 '24 actual $1.38, beat Q2 '25 estimate $1.39 Q2 '25 actual $1.44, beat Q3 '25 estimate $1.44 Q3 '25 actual $1.45, match Q4 '25 estimate $1.32 Q4 '25 actual $1.30, miss Q1 '26 estimate $1.25 Q1 '26 actual $1.32, beat Q2 '26 estimate $1.48 Q3 '26 estimate $1.51 Q4 '26 estimate $1.37 Q1 '27 estimate $1.36

Analyst Consensus ?

ConsensusBuy26 ratings
Bullish1661.5%
Neutral934.6%
Bearish13.9%

Analyst 52W Price Targets

$74.82Current
$45Low
$59.36Average
$79High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
UBS Buy BuyMaintainJul 7, 2026
Barclays Underweight UnderweightMaintainMay 15, 2026
Citigroup Neutral NeutralMaintainMay 1, 2026
B of A Securities Buy BuyMaintainApr 10, 2026
Stifel Buy BuyMaintainJan 30, 2026
Morgan Stanley Equal Weight Equal WeightMaintainJul 31, 2025
Deutsche Bank Buy BuyMaintainNov 1, 2024
Jefferies Buy BuyMaintainOct 13, 2023
Cowen & Co. Market Perform Market PerformMaintainJun 27, 2022
Bernstein Market Perform OutperformDowngradeMay 10, 2022
RBC Capital Sector Perform OutperformDowngradeMar 28, 2022
Goldman Sachs Buy NeutralUpgradeMar 22, 2022
Argus Research Hold BuyDowngradeMay 5, 2021
CFRA Hold HoldMaintainApr 30, 2020
Piper Sandler Overweight NeutralUpgradeJan 31, 2020
Citi Buy NeutralUpgradeDec 2, 2019
Piper Jaffray Neutral OverweightDowngradeSep 10, 2019
Bank of America Buy BuyMaintainMar 20, 2019
Argus Buy BuyMaintainOct 29, 2018
Stifel Nicolaus Buy BuyMaintainJul 27, 2018
PiperJaffray Overweight OverweightMaintainFeb 2, 2018
Berenberg Buy HoldUpgradeDec 19, 2017
Edward Jones Buy HoldUpgradeNov 1, 2017
CLSA Outperform OutperformMaintainSep 15, 2016
Nomura Buy NeutralUpgradeJan 16, 2015
Wells Fargo Market Perform OutperformDowngradeMay 19, 2014
Show less

Named analyst price targets

Upside is calculated against the persisted current price $74.82. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
UBSFaham Baig$79$73.5 +5.6%Jul 7, 2026
BarclaysAnalyst unavailable$64$72.41 -14.5%May 15, 2026
Deutsche BankDamian McNeela$66$73.83 -11.8%May 4, 2026
UBSAnalyst unavailable$76$72.94 +1.6%May 1, 2026
Stifel NicolausAnalyst unavailable$77$72.64 +2.9%May 1, 2026
Morgan StanleyAnalyst unavailable$71$72.64 -5.1%May 1, 2026
Goldman SachsAnalyst unavailable$77$72.64 +2.9%Apr 30, 2026
UBSFaham Baig$74$67.04 -1.1%Mar 9, 2026
BarclaysPallav Mittal$63$67.57 -15.8%Feb 23, 2026
Stifel NicolausAnalyst unavailable$68$59.76 -9.1%Jan 30, 2026
UBSAnalyst unavailable$67$62.92 -10.5%Jan 26, 2026
UBSAnalyst unavailable$63$55.9 -15.8%Jan 9, 2026
JefferiesAndrei Andon-Ionita$47$56.67 -37.2%Nov 4, 2025
UBSFaham Baig$61$57.13 -18.5%Oct 31, 2025
Stifel NicolausMatthew Smith$72$67.68 -3.8%Aug 21, 2025
Deutsche BankDamian McNeela$60$58.79 -19.8%Apr 1, 2025
UBSFaham Baig$46$58.79 -38.5%Apr 1, 2025
BarclaysGaurav Jain$46$54.14 -38.5%Nov 6, 2024
Stifel NicolausMatthew Smith$60$53.87 -19.8%Nov 1, 2024
Bank of America SecuritiesLisa Lewandowski$53$49.86 -29.2%Oct 15, 2024
Bank of America SecuritiesLisa Lewandowski$57$54.07 -23.8%Sep 4, 2024
Stifel NicolausMatthew Smith$54$49.01 -27.8%Aug 1, 2024
Stifel NicolausMatthew Smith$50$46.77 -33.2%Jun 7, 2024
Goldman SachsBonnie Herzog$47$44.28 -37.2%Mar 14, 2024
Morgan StanleyPamela Kaufman$45$42.91 -39.9%Sep 22, 2023
CitigroupAdam Spielman$47$45.94 -37.2%May 4, 2023
Stifel NicolausMatthew Smith$52$46.43 -30.5%Apr 24, 2023
BMO CapitalKenneth Zaslow$46$47.58 -38.5%Feb 17, 2023
CitigroupAnalyst unavailable$49.5$46.44 -33.8%Feb 7, 2023
Goldman SachsBonnie Herzog$59$41.77 -21.1%Jun 30, 2022
BarclaysGaurav Jain$36$43.19 -51.9%Jun 29, 2022
Morgan StanleyPamela Kaufman$43$42.42 -42.5%Jun 24, 2022
Morgan StanleyPamela Kaufman$50$54.01 -33.2%Jun 8, 2022
JefferiesOwen Bennett$58$51.09 -22.5%May 23, 2022
BernsteinCallum Elliott$53$55.26 -29.2%May 10, 2022
Cowen & Co.Vivien Azer$53$54.45 -29.2%Apr 11, 2022
Piper SandlerMichael Lavery$57$43.91 -23.8%Sep 30, 2021
BarclaysGaurav Jain$45$45.21 -39.9%Aug 2, 2021
BernsteinCallum Elliott$59$45.95 -21.1%Jun 1, 2021
Show less

Track every rating change on MO the moment it posts. Free to start.

Start free

Market reaction

prior-close to event-session close
Stock move +6.5% Event window
SPY move +1.0% Same window
Abnormal move +5.5% Stock minus SPY
Volume 3.0× Versus trailing sessions
Subsequent drift -4.2% Up to 20 sessions
MOSPY benchmark

Follow MO with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Compared to the prior quarter (Q4 2025), where adjusted EPS grew 4.4% and the narrative centered on FDA authorizations for Helix ON PLUS and the launch of the duty drawback program, Q1 2026 showed several notable shifts. EPS growth accelerated to 7.3% YoY. on! PLUS moved from authorization to nationwide availability at ~100,000 stores, while Helix shipped 18% more volume. Marlboro's premium share climbed to 59.5%, and Basic captured additional discount share, demonstrating effective portfolio management across price tiers. The e-vapor category showed early signs of moderation as enforcement actions curtailed illicit disposable products, a dynamic management had flagged in the prior quarter when illicit e-vapor accounted for ~70% of the category. New initiatives include the upcoming Cowboy Cut Marlboro variant and continued on! PLUS flavor and strength expansion. Notably, capex outlook shifted from 'increasing' in Q4 2025 to 'not mentioned' in Q1 2026, suggesting the initial investment cycle may be stabilizing.

Guidance delta

Full-year 2026 adjusted EPS guidance of $5.56-$5.72 was reaffirmed despite the stronger Q1 print. Management cited expectations of more balanced growth between H1 and H2, implying a deceleration in subsequent quarters. This maintained guidance, rather than a raise, was a focal analyst concern given the Q1 beat created a ~$0.07 EPS cushion above the $1.25 consensus.

Key takeaways

  • Adjusted diluted EPS of $1.32 beat consensus by 5.6%, with revenue of $4.76B exceeding estimates by 3.9%.
  • Marlboro premium share rose to 59.5%, while Basic captured additional discount segment share.
  • Helix delivered an 18% shipment volume increase; on! PLUS reached nationwide availability at ~100,000 stores.
  • on! PLUS is the first nicotine pouch authorized under the FDA's pilot program, using proprietary NICOSILK technology.
  • E-vapor demand showed early signs of moderation as enforcement curtailed illicit flavored disposable products.
  • The stock rose 6.5% on the report but subsequently drifted -4.2%, suggesting the market initially rewarded the beat then reconsidered the unchanged guidance.

Management priorities

  • Continue national expansion of on! PLUS and pursue FDA approvals for additional flavors and strengths.
  • Launch Cowboy Cut, a competitively priced Marlboro variant, later in the year.
  • Invest in smoke-free product innovation and advocate for faster FDA authorization timelines.
  • Maintain dividend payouts and share repurchase program while managing debt levels.
  • Grow duty drawback export volumes to incrementally increase the financial benefit throughout 2026.

Related earnings events

Consumer Defensive

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-29T00:01:55.007879+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T00:01:55.004011+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.